Adalimumab biosimilar (180 Therapeutics)

阿达木单抗生物类似药 (180 Therapeutics)

Report date: 2024/12/30 10:32:32

Base Information

Drug NameAdalimumab biosimilar (180 Therapeutics)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPostoperative Cognitive ComplicationsMetabolic Dysfunction-Associated Steatotic Liver DiseasePeriarthritis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator Companies180 Therapeutics Lp
China Registration ClassN/A

Develop Information

Active Companies180 Life Sciences Corp
Inactive CompaniesN/A
Active IndicationsPostoperative Cognitive ComplicationsMetabolic Dysfunction-Associated Steatotic Liver DiseasePeriarthritis +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AB04
Related LinksN/A